xenoport inc (XNPT) Key Developments
Xenoport, Inc. Reports New Expert Recommendations for the Prevention and Treatment of Augmentation in Patients Suffering from Restless Legs Syndrome
Jun 8 15
XenoPort, Inc. reported that new expert recommendations for the prevention and treatment of augmentation in patients suffering from restless legs syndrome (RLS) list gabapentin enacarbil as a first-line therapy with a lower risk of developing augmentation. In addition, gabapentin enacarbil is listed as an alternative treatment for the management of patients suffering from augmentation who were previously treated with dopaminergic medication. RLS augmentation is an insidious worsening of RLS symptoms that can occur after treatment of RLS with dopaminergic medication. The recommendations were created by the combined Task Force from the International RLS Study Group (IRLSSG), the European RLS Study Group (EURLSSG) and the RLS Foundation. HORIZANT® (gabapentin enacarbil) Extended-Release Tablets is the only non-dopaminergic medication and the only alpha-2-delta calcium-channel ligand class medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe primary RLS in adults.
Xenoport, Inc. to Present New Pooled Data Analyses on Horizant at the 2015 Sleep Annual Meeting
Jun 2 15
Xenoport, Inc. announced that pooled data analyses for HORIZANT (gabapentin enacarbil) Extended-Release Tablets, will be presented at the upcoming 29th Associated Professional Sleep Societies (APSS) annual SLEEP meeting in Seattle. The presentations include: Association Between Pain and Symptoms of Restless Legs Syndrome (RLS) in adults with moderate-to-severe. Primary RLS in a Combined Treatment Population: Pooled Analyses From 3 Randomized Controlled Trials. Poster #253, June 10, 205, Exhibit Hall 4AB. The Effect of Gabapentin Enacarbil on Pain Outcomes and Restless Legs Syndrome Symptoms in adults with moderate-to-severe primary RLS: Pooled Analyses From 3 Randomized, Controlled Trials. Poster #256, June 10, 2015, Exhibit Hall 4AB.
Xenoport, Inc. Approves Amendments to Amended and Restated Certificate of Incorporation
May 22 15
Xenoport, Inc. announced at the AGM held on May 19, 2015, it has approved amendments to the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock and approved amendments to the charter and company's amended and restated bylaws to eliminate the supermajority voting requirement for amendments to XenoPort's amended and restated bylaws.
Xenoport, Inc. Provides Sales Outlook for the Year 2015
May 21 15
Xenoport, Inc. provided sales outlook for the year 2015. For the period, the company expects net sales to be in the range of $39 million to $43 million.
Xenoport, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 10:00 AM
May 18 15
Xenoport, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.